Company intelligence / Profile preview
Celltrion
Incheon, Incheon, South Koreacelltrion.com ↗
- Ownership
- Public · 068270
- Employees
- ~2000
- Development stage
- Other
01
Overview
Celltrion pioneered the world’s first monoclonal antibody biosimilar (“Remsima”) and has since become Korea’s largest exporter of biologics. The company has received regulatory approvals for numerous mAb-based therapies across autoimmune diseases and oncology. Recent FDA approvals include interchangeable designations for adalimumab (“Yuflyma”), omalizumab (“Omlyclo”), denosumab (“Osenvelt”, “Stoboclo”), tocilizumab (“Avtozma”), ustekinumab (“Steqeyma”) among others. Clinical data demonstrate comparable efficacy/safety to reference products with long-term maintenance results in inflammatory bowel disease.[1][2][3][4]
- Therapeutic areas
- GastroenterologyRheumatologyEndocrinologyDermatologyOncologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)BiosimilarsNovel biopharmaceuticals[1][3]Vaccines[3]
- Industry
- Biotech
02
Drug pipeline
40 assets39 more assets in the full pipeline.
03
Partnerships
Partnerships with major pharmaceutical companies for commercialization/distribution are common but specific partners are not listed in these sources.
04
Financials
- Market cap
- $35.6B
- Total revenue
- $3.1B
- Enterprise value
- $37.5B
Beyond the preview
Go deeper on Celltrion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celltrion.